[HIGHLIGHTS] (m+) How the pharmaceutical company Novo Nordisk increases its profits from the obese people of the Western world

Lars Fruergaard Jørgensen has pushed Novo Nordisk with his kilokillers into the most valuable stock exchange company in Europe. The side effect: It could overwhelm the state health systems with its breathtaking pricing policy.

Read the manager magazine and the Harvard Business Manager as an e-paper in the app. All content from m+ and HBm+ on the manager-magazin.de website and in the manager news app. The content of the printed magazines including e- paper (PDF)